Euticals to buy Archimica to expand manufacturing base
Archimica confirmed the deal, explaining that: “[The firms] expect the combination to be strategic, creating new opportunities to further develop business activities in the fine chemicals sector.
The acqusition, which is due to close next month, will include Archimica’s 550-strong workforce and network of six manufacturing sites, including one in the US that was formerly owned by Swiss drugmaker Roche.
In Europe, Archimica operates manufacturing sites in Bon-Encontre and Tonneins in south-west France, a synthesis centre in Frankfurt, Germany and a bulk API production facility in Sandycroft, Wales.
The firm also runs a current good manufacturing practices (cGMP) standard facility in Origgio in northern Italy that has passed numerous US Food and Drug Administration (FDA) inspections since 1975, the most recent of which was last year.
Manufacturing expansion
For active pharmaceutical ingredient (API) maker Euticals, which is a unit of Sino-Italian investment group Mandarin Capital Partners, the Archimica acquisition fits with the expansion plan it began last year.
In March the firm bought fellow Italy-based drug ingredient maker Polichimica to expand its network of four manufacturing plants in Lombardia with a facility in nearby Rozzano, Milan.
At the time Euticals CEO Maurizio Silvestri said the purpose of the Polichimica deal was to “increase the production, the business volume and the penetration in new markets.”
He also set out the firm’s wider plan to expand its manufacturing business through more takeovers, explaining that: “Our goal is to look to the Far East for new acquisitions, primarily in China.
“We also want to expand our presence in India, Japan and South America. The number of individuals who can access to drugs does grow in countries like India and China, where GDP increases significantly.